Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer

A paper published in The Oncologist last month analysed real-world data to further evaluate the effectiveness of first-line sunitinib in patients with metastatic renal cell carcinoma (mRCC) with favourable, intermediate or poor risk disease according to the International mRCC Database Consortium (IMDC) risk criteria. The study included 1769 patients; 318 (18.0%) had favourable risk, 1031 […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

Developments in data for rare and less common cancers

Cancer52 and the National Cancer Registration and Analysis Service (NCRAS) at Public Health England (PHE) are delighted to be able to share a film and a report of the very successful Developments in Data for Rare and Less Common Cancers event held on 22nd May 2019. The report provides a written overview of the whole event and the film includes snippets […]

read more

Data-driven approach to personalised care

One of the greatest strengths of the NHS is its comprehensive datasets of the population from birth to death. A recent paper proposes a new model of cancer care and looks at how data could be examined and used at every stage of the treatment journey, from prevention and diagnosis through to treatment and recovery. […]

read more

NICE exploring ways to use real world data

The National Institute of Health and Care Excellence (NICE) is planning to extend its use of real world data to help inform its independent committees who produce its guidance. NICE already makes use of a wide range of published scientific evidence for its guidance for the NHS on health technologies for a range of medical […]

read more

Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer

A retrospective study using data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) dataset looked at the efficacy of nivolumab (225 patients) and cabozantinib (53 patients) when used to treat metastatic renal cell carcinoma (RCC) in the real world. The study found similar outcomes for patients treated with nivolumab and cabozantinib in the […]

read more

Real world evidence as a complement to clinical trials

The review article highlights the usefulness of real world evidence to add substantially to the information available to the scientific and medical communities. Randomised clinical trials have traditionally been the gold-standard for scientific evidence. However, randomised clinical trials are not able to answer all the questions necessary for clinical decision-making. Real world evidence refers to […]

read more

ESMO 2018: Interviews with the kidney cancer experts

The following video interviews with kidney cancer experts from the USA and Europe were conducted at the recent European Society of Medical Oncology (ESMO) 2018 congress in Munich last month. The interviews cover topics such as a new treatment for VHL-associated kidney cancer, real world effectiveness of pazopanib for renal cell carcinoma (RCC), recommendations for […]

read more

Implications of real world data on the use of first-line pazopanib for the management of metastatic kidney cancer

The following interview with Dr Eric Jonasch, medical oncologist from MD Anderson Cancer Centre in Texas, USA, discusses the implications of real world data on the use of first-line pazopanib for the management of metastatic renal cell carcinoma (RCC). Dr Jonasch was interviewed at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. Watch Dr Jonasch’s interview […]

read more

Real world experience with pazopanib in patients with advanced/metastatic kidney cancer

Results from the PRINCIPAL study to evaluate the real world effectiveness and safety of pazopanib in patients with advanced/metastatic renal cell carcinoma (RCC) were presented at the 2018 American Society for Clinical Oncology (ASCO) meeting in Chicago this week. PRINCIPAL is the largest prospective real world study of pazopanib in patients with RCC. All patients aged […]

read more
Showing 1 to 10 of 12 results
  TOP